Methicillin-resistant Staphylococcus aureus infections: A review of the currently available treatment options

Rodvold, 2014, Methicillin-resistant Staphylococcus aureus therapy: past, present and future, Clin Infect Dis, 58, S20, 10.1093/cid/cit614 Gould, 2012, New insights into methicillin-resistant Staphylococcus aureus pathogenesis, treatment and resistance, Int J Antimicrob Agents, 39, 96, 10.1016/j.ijantimicag.2011.09.028 Stryewski, 2014, Methicillin-resistant Staphylococcus aureus: an evolving pathogen, Clin Infect Dis, 58, S10, 10.1093/cid/cit613 US Centers for Disease Control and Prevention, 2012 Bassetti, 2014, European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid, Clin Microbiol Infect, 20, 3, 10.1111/1469-0691.12463 Gould, 2011, Management of serious methicillin-resistant Staphylococcus aureus infection: what are the limits?, Int J Antimicrob Agents, 37, 202, 10.1016/j.ijantimicag.2010.10.030 Schilling, 2011, Vancomycin: a 50-something-year-old antibiotic we still don’t understand, Cleve Clin J Med, 78, 465, 10.3949/ccjm.78a.10168 Holmes, 2015, Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond, Semin Respir Crit Care Med, 36, 17, 10.1055/s-0034-1397040 Liu, 2011, Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Clin Infect Dis, 52, e18, 10.1093/cid/ciq146 Campanile, 2010, Heteroresistance to glycopeptides in Italian methicillin-resistant Staphylococcus aureus (MRSA) isolates, Int J Antimicrob Agents, 36, 415, 10.1016/j.ijantimicag.2010.06.044 Khatib, 2011, Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia, J Antimicrob Chemother, 66, 1594, 10.1093/jac/dkr169 Satola, 2011, J Clin Microbiol, 49, 1583, 10.1128/JCM.01719-10 Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrob Agents Chemother, 53, 3447, 10.1128/AAC.01365-08 Bae, 2009, Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance, J Infect Dis, 200, 1355, 10.1086/606027 Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202 Edwards, 2012, Is vancomycin ‘MIC creep’ method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010, J Clin Microbiol, 50, 318, 10.1128/JCM.05520-11 Kalil, 2014, Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis, JAMA, 312, 1552, 10.1001/jama.2014.6364 Cafiso, 2012, Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains, PLoS One, 7, e29573, 10.1371/journal.pone.0029573 Ludwig, 2012, Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus, J Clin Microbiol, 50, 3383, 10.1128/JCM.01158-12 Vandecasteele, 2013, The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties, J Antimicrob Chemother, 68, 743, 10.1093/jac/dks495 Bradley, 2014, Which antibiotic for resistant Gram-positives, and why?, J Infect, 68, S63, 10.1016/j.jinf.2013.09.016 Wu, 2011, Daptomycin: evaluation of a high-dose treatment strategy, Int J Antimicrob Agents, 38, 192, 10.1016/j.ijantimicag.2011.03.006 Fenton, 2004, Daptomycin, Drugs, 64, 445, 10.2165/00003495-200464040-00009 Gould, 2013, Daptomycin: the role of high-dose and combination therapy for Gram-positive infections, Int J Antimicrob Agents, 42, 202, 10.1016/j.ijantimicag.2013.05.005 Liu, 2011, Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary, Clin Infect Dis, 52, 285, 10.1093/cid/cir034 Kullar, 2011, High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study, Pharmacotherapy, 31, 527, 10.1592/phco.31.6.527 Benvenuto, 2006, Pharmacokinetics and tolerability of daptomycin at doses up to 12milligrams per kilogram of body weight once daily in healthy volunteers, Antimicrob Agents Chemother, 50, 3245, 10.1128/AAC.00247-06 Moise, 2009, Safety and clinical outcomes when utilizing high-dose (≥8mg/kg) daptomycin therapy, Ann Pharmacother, 43, 1211, 10.1345/aph.1M085 Patel, 2009, Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 53, 5141, 10.1128/AAC.00307-09 Mishra, 2014, Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons, PLoS One, 9, e107426, 10.1371/journal.pone.0107426 Cafiso, 2014, dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus, Int J Antimicrob Agents, 43, 26, 10.1016/j.ijantimicag.2013.10.001 Stefani, 2015, Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence, Int J Antimicrob Agents, 46, 278, 10.1016/j.ijantimicag.2015.05.008 Barber, 2014, Observation of ‘seesaw effect’ with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains, Infect Dis Ther, 3, 35, 10.1007/s40121-014-0023-0 Werth, 2013, Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the ‘seesaw effect’, Antimicrob Agents Chemother, 57, 2664, 10.1128/AAC.02308-12 Mehta, 2012, β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives, Antimicrob Agents Chemother, 56, 6192, 10.1128/AAC.01525-12 Rose, 2012, Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity, Antimicrob Agents Chemother, 56, 5296, 10.1128/AAC.00797-12 Bounthavong, 2011, Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis, Value Health, 14, 631, 10.1016/j.jval.2010.12.006 Leone, 2015, Methicillin-resistant Staphylococcus aureus infections: role of daptomycin/β-lactams combination, Infez Med, 23, 99 Stalker, 2003, Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial, Clin Pharmacokinet, 42, 1129, 10.2165/00003088-200342130-00004 Pea, 2012, Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients, J Antimicrob Chemother, 67, 2034, 10.1093/jac/dks153 Pharmacia Ltd, 2011 Itani, 2010, Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus, Am J Surg, 199, 804, 10.1016/j.amjsurg.2009.08.045 Chavanet, 2013, The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia, Med Mal Infect, 43, 451, 10.1016/j.medmal.2013.09.011 Wu, 2006, High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease, Clin Infect Dis, 42, 66, 10.1086/498509 Meka, 2004, Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA, J Infect Dis, 190, 311, 10.1086/421471 Toh, 2007, Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, Mol Microbiol, 64, 1506, 10.1111/j.1365-2958.2007.05744.x Barriere, 2014, The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia, Future Microbiol, 9, 281, 10.2217/fmb.14.4 Mendes, 2012, Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents, Antimicrob Agents Chemother, 56, 3999, 10.1128/AAC.00011-12 Leonard, 2011, Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA), Int J Antimicrob Agents, 37, 558, 10.1016/j.ijantimicag.2011.02.007 Torres, 2014, Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure, J Antimicrob Chemother, 69, 1119, 10.1093/jac/dkt490 Jones, 2013, Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011), Diagn Microbiol Infect Dis, 75, 304, 10.1016/j.diagmicrobio.2012.11.024 Dunne, 2016, A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection, Clin. Infect. Dis., 62, 545, 10.1093/cid/civ982 Citron, 2014, Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains, Diagn Microbiol Infect Dis, 79, 438, 10.1016/j.diagmicrobio.2014.05.014 Boucher, 2014, Once-weekly dalbavancin versus daily conventional therapy for skin infection, N Engl J Med, 370, 2169, 10.1056/NEJMoa1310480 Esposito, 2015, Dalbavancin for the treatment of acute bacterial skin and skin structure infections, Infez Med, 23, 313 Ambrose, 2012, In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans, Clin Infect Dis, 54, S220, 10.1093/cid/cis001 Arhin, 2010, Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008, Int J Antimicrob Agents, 36, 474, 10.1016/j.ijantimicag.2010.07.010 Lin, 2014, Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents, Antimicrob Agents Chemother, 58, 6251, 10.1128/AAC.02932-14 Corey, 2015, Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study, Clin Infect Dis, 60, 254, 10.1093/cid/ciu778 Corey, 2014, Single-dose oritavancin in the treatment of acute bacterial skin infections, N Engl J Med, 370, 2180, 10.1056/NEJMoa1310422 Muller, 2014, Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia, Antimicrob Agents Chemother, 58, 2512, 10.1128/AAC.02611-13 El Solh, 2009, Ceftobiprole: a new broad spectrum cephalosporin, Expert Opin Pharmacother., 10, 1675, 10.1517/14656560903048967 Pillar, 2008, In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin, J Antimicrob. Chemother., 61, 595, 10.1093/jac/dkm492 Liapikou, 2015, Ceftobiprole for the treatment of pneumonia: a European perspective, Drug Des. Devel. Ther., 18, 4565 Farrell, 2014, Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010, Antimicrob. Agents Chemother., 58, 3882, 10.1128/AAC.02465-14 Rossolini, 2011, Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study, J. Antimicrob. Chemother., 66, 151, 10.1093/jac/dkq397 Awad, 2014, A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia, Clin Infect Dis, 59, 51, 10.1093/cid/ciu219 European Medicines Agency, 2016 Friedland, 2012, CANVAS 1 and 2: analysis of clinical response at Day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections, Antimicrob Agents Chemother, 56, 2231, 10.1128/AAC.05738-11 Farrell, 2012, In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008–2010), Clin Infect Dis, 55, S206, 10.1093/cid/cis563 Tattevin, 2014, Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicenter observational study, J Antimicrob Chemother, 69, 2010, 10.1093/jac/dku085 Saravolatz, 2010, In vitro activity of ceftaroline against community associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates, Antimicrob Agents Chemother, 54, 3027, 10.1128/AAC.01516-09 Shaw, 2008, In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains, Antimicrob Agents Chemother, 52, 4442, 10.1128/AAC.00859-08 Zhanel, 2015, Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens, Drugs, 75, 253, 10.1007/s40265-015-0352-7 Noel, 2012, A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections, Antimicrob Agents Chemother, 56, 5650, 10.1128/AAC.00948-12 Russo, 2016, Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections, Clin Microbiol Infect, 22, S27, 10.1016/S1198-743X(16)30095-7 Esposito, 2016, Epidemiology and microbiology of skin and soft tissue infections, Curr Opin Infect Dis, 29, 109, 10.1097/QCO.0000000000000239 Lipsky, 2012, A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes, BMC Infect Dis, 12, 227, 10.1186/1471-2334-12-227 Esposito, 2011, Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy, J Chemother, 23, 251, 10.1179/joc.2011.23.5.251 Moran, 2013, Acute bacterial skin infections: developments since the 2005 Infectious Disease Society of America (IDSA) guidelines, J Emerg Med, 44, e397, 10.1016/j.jemermed.2012.11.050 Grim, 2005, Trimethoprim–sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus, Pharmacotherapy, 25, 253, 10.1592/phco.25.2.253.56956 Corey, 2010, CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections, J Antimicrob Chemother, 65, iv41 Wilcox, 2010, CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections, J Antimicrob Chemother, 65, iv53 Yue, 2013, Linezolid versus vancomycin for skin and soft tissue infections, Cochrane Database Syst Rev, CD008056 National Institute for Health and Clinical Excellence, 2016 Sharpe, 2005, Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus, Am J Surg, 189, 425, 10.1016/j.amjsurg.2005.01.011 Stryjewski, 2008, Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by Gram-positive organisms, Clin Infect Dis, 46, 1683, 10.1086/587896 Belley, 2010, Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing, Antimicrob Agents Chemother, 54, 5369, 10.1128/AAC.00760-10 Zhanel, 2012, Oritavancin: mechanism of action, Clin Infect Dis, 54, S214, 10.1093/cid/cir920 Chen, 2007, Dalbavancin: a novel antimicrobial, Int J Clin Pract, 61, 853, 10.1111/j.1742-1241.2007.01318.x Mendes, 2012, Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline, J Antimicrob Chemother, 67, 1321, 10.1093/jac/dks069 Kullar, 2016, When sepsis persists: a review of MRSA bacteraemia salvage therapy, J Antimicrob Chemother, 71, 576, 10.1093/jac/dkv368 Mermel, 2009, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 49, 1, 10.1086/599376 Murray, 2013, Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1mg/L: a matched cohort study, Clin Infect Dis, 56, 1562, 10.1093/cid/cit112 Moore, 2012, Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case–control study, Clin Infect Dis, 54, 51, 10.1093/cid/cir764 Schwalm, 2004, Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment, Can J Infect Dis Med Microbiol, 15, 97 Jang, 2009, Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem, Clin Infect Dis, 49, 395, 10.1086/600295 Park, 2012, Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia, J Infect, 65, 505, 10.1016/j.jinf.2012.08.007 Fu, 2013, The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections, PLoS One, 8, e58240, 10.1371/journal.pone.0058240 Shorr, 2005, Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies, J Antimicrob Chemother, 56, 923, 10.1093/jac/dki355 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085249.htm. Last accessed 21 september 2016. Ho, 2012, Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy, J Antimicrob Chemother, 67, 1267, 10.1093/jac/dks006 Lin, 2013, The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients, J Infect Chemother, 19, 42, 10.1007/s10156-012-0449-9 Najjar, 2014, Treatment of methicillin-resistant Staphylococcus aureus bacteremia and prosthetic valve endocarditis with ceftaroline, Infect Dis Clin Pract, 22, 108, 10.1097/IPC.0b013e318287c73f Oltolini, 2016, Meticillin-resistant Staphylococcus aureus endocarditis: first report of daptomycin plus ceftobiprole combination as salvage therapy, Int. J. Antimicrob. Agents, 47, 502, 10.1016/j.ijantimicag.2016.04.006 Stryjewski, 2014, A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study, BMC Infect Dis, 14, 289, 10.1186/1471-2334-14-289 Lew, 2004, Osteomyelitis, Lancet, 364, 369, 10.1016/S0140-6736(04)16727-5 Costerton, 2003, The application of biofilm science to the study and control of chronic bacterial infections, J Clin Invest, 112, 1466, 10.1172/JCI200320365 Perlroth, 2008, Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature, Arch Intern Med, 168, 805, 10.1001/archinte.168.8.805 Bernard, 2001, Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost, J Clin Pharm Ther, 26, 445, 10.1046/j.1365-2710.2001.00380.x Byren, 2012, Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty, Antimicrob Agents Chemother, 56, 5626, 10.1128/AAC.00038-12 Parra-Ruiz, 2010, Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm, Antimicrob Agents Chemother, 54, 4329, 10.1128/AAC.00455-10 Niska, 2013, Vancomycin–rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection, Antimicrob Agents Chemother, 57, 5080, 10.1128/AAC.00702-13 Rayner, 2004, Linezolid in the treatment of osteomyelitis: results of a compassionate use experience, Infection, 32, 8, 10.1007/s15010-004-3029-9 Falagas, 2007, Linezolid for the treatment of adults with bone and joint infections, Int J Antimicrob Agents, 29, 233, 10.1016/j.ijantimicag.2006.08.030 Tremblay, 2013, Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?, Ann Pharmacother, 47, 1045, 10.1345/aph.1R726 Wunderink, 2012, Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled trial, Clin Infect Dis, 54, 621, 10.1093/cid/cir895 Jiang, 2013, Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials, Eur J Clin Microbiol Infect Dis, 32, 1121, 10.1007/s10096-013-1867-z Kalil, 2013, Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis, BMJ Open, 3, e003912, 10.1136/bmjopen-2013-003912 Kalil, 2010, Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis, Crit Care Med, 38, 1802, 10.1097/CCM.0b013e3181eb3b96 Walkey, 2011, Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials, Chest, 139, 1148, 10.1378/chest.10-1556 Bhan, 2015, Linezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumonia, PLoS One, 10, e0114574, 10.1371/journal.pone.0114574